Recurrent Squamous Cell Carcinoma of the Larynx Completed Phase 2 Trials for Cetuximab (DB00002)

DBCOND0028811 (Recurrent Squamous Cell Carcinoma of the Larynx)Completed2 IdentifierTitlePurposeDrugs
NCT01316757Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell CancerTreatment
NCT00939627Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent CetuximabTreatment